Skip to main content
Clinical Trials/ACTRN12618000528257
ACTRN12618000528257Active, not recruiting未知

Sentinel Lymph Node Biopsy (SLNB) in Early-stage (cT1N0) Merkel Cell Carcinoma (MCC) to estimate the rate of SLNB positivity in cT1N0 MCC

South Western Sydney Local Health District0 sites29 target enrollmentStarted: April 10, 2018Last updated:

Trial Snapshot

Phase
未知
Status
Active, not recruiting
Enrollment
29

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to o limit (—)
Sex
All

Inclusion Criteria

  • Patients (male or female) above 18 years old
  • Histologically documented cutaneous MCC, stage cT1N0
  • Suitable for sentinel lymph node biopsy
  • No clinical evidence of regional or distant metastases.
  • Patients must undergo treatment and follow up at Peter MacCallum Cancer Centre, Melbourne or the Liverpool hospital, Sydney.

Exclusion Criteria

  • Proven metastatic disease
  • Patients who refuse radiotherapy
  • Patients who refuse to join the trial or are unable to consent
  • Patients not being considered for further therapy
  • Patients who cannot lie still for at least 30 minutes or comply with imaging
  • Technically unsuitable for for lymphoscintigraphy/ SNB procedure
  • Pregnancy/Lactation

Investigators

Similar Trials